**About STADA**

**STADA Arzneimittel AG** is an international pharmaceutical company that has been following its purpose **"Caring for people’s health as a trusted partner"** for more than 125 years. STADA strives to ensure that its drug products are a trustworthy choice of healthcare professionals and consumers in all countries of its presence.

STADA's zero hour is March 14, 1895 in the German city of Dresden when forward-looking pharmacists teamed up to economically produce joint preparations to ensure effective and affordable public health in line with the uniform quality standards. The company name is abbreviated from St.d.A-Standardarzneimittel deutscher Apotheker, which means the Standard of German Pharmacists.

Worldwide, STADA sells its products **in approximately 120 countries**, including Russia and CIS.

STADA's key business areas **are Consumer Healthcare,** **generics**, and **specialty generics**. The company continues expanding its business in these areas, both organically and through acquisitions.

As an international company, we focus on the internationalization of our production and business, while remaining a local market player in each region. STADA Group includes **more** **than 20 production facilities worldwide**, including two Russian sites – Nizhpharm (Nizhny Novgorod) and Hemofarm (Obninsk).

The production site **Nizhpharm (Nizhny Novgorod) became a part of STADA in 2004**. It is the largest Russian manufacturer of semi-solid dosage forms (ointments, suppositories, gels). The production site with a century-old history was the first to confirm compliance with international GMP quality standards in Russia.

**In 2010**, the production site Hemofarm **(Obninsk)** became part of the Group. This is the first large-scale foreign production established in the Obninsk municipal industrial zone from which the industrial parks of the Kaluga Region grew later.

Today, STADA has one of the deepest levels of **localization – more than 65%,** and continues investing in this direction.

STADA employs **more than 2,500 employees in Russia and CIS region**.

STADA is a company with an extensive portfolio. **In Russia, it includes more than 170 products** meeting the high standards of traditional German quality. Thus, we provide millions of patients with medicines for the treatment of chronic diseases, give them the opportunity to prevent the development of diseases and take daily care of their health and the health of their loved ones improving their life quality.

STADA product portfolio in Russia includes medicines **from 17 of 20 therapeutic groups, the most popular drugs in the pharmacy retail.**

STADA is one of the largest manufacturers in the Consumer Healthcare, generics and specialty generics.

Medicines manufactured by STADA meet the most important expectations: they are safe, effective and affordable.

In Russia, STADA **is a partner with 61 pharmacy chains.** These include 46,000 pharmacies.

The company is also the largest foreign investor in the Russian pharmaceutical business. STADA's investments in 2020 amounted to 660 mio USD, and in total, according to E&Y, **STADA's investments** in the development of the Russian pharmaceutical industry over the past 15 years **have exceeded 1 billion US dollars**.

The company's headquarters is located in Bad Vilbel (Germany).

Visit us online at www.stada.ru

\* Based on total sales of the company's own products and the acquired portfolio of Takeda and GSK including sales of the Aqualor brand - according to IQVIA, FY2019, all market segments.

\*\* Based on total sales of the company's own products and the acquired portfolio of Takeda including sales of the Aqualor brand - according to IQVIA, FY2019, all market segments.